The Effect of Targeted Therapy for Genitourinary Malignancies on Sexual Function and Fertility.

Document Type

Article

Publication Date

8-1-2017

Publication Title

Current urology reports

Abstract

PURPOSE OF REVIEW: Targeted therapy for genitourinary cancer is being used at an increasing rate. These medications show great survival benefit but are relatively lacking in long-term adverse effect data. With increasing survivability, measures to improve quality of life must be considered for GU cancer and a large proponent of this is sexual function.

RECENT FINDINGS: mTOR inhibitors have shown an effect on testosterone levels and may have a link to abnormal semen parameters. Tyrosine kinase inhibitors (TKIs) have shown no adverse sexual outcomes in the literature. There are laboratory links to tyrosine kinases having a beneficial effect on erectile and sexual function. Possible sexual side effects must be discussed with patients receiving a diagnosis of cancer. Further research is required to determine the exact mechanisms and outcomes of sexual function with new and emerging targeted therapy.

Medical Subject Headings

Animals; Fertility; Humans; Male; Molecular Targeted Therapy; Penile Erection; Protein Kinase Inhibitors; Quality of Life; Sexual Dysfunction, Physiological; Sexuality; TOR Serine-Threonine Kinases; Urogenital Neoplasms

PubMed ID

28712040

Volume

18

Issue

8

First Page

65

Last Page

65

Find It @ Sladen

Share

COinS